Castle biosciences stock.

The estimated net worth of Daniel Bradbury is at least $1.27 million as of November 20th, 2023. Mr. Bradbury owns 63,885 shares of Castle Biosciences stock worth more than $1,270,034 as of November 24th. This net worth evaluation does not reflect any other assets that Mr. Bradbury may own. Learn More about Daniel Bradbury's net worth.1 Nis 2022 ... TAKEAWAY: 48% Chance Of Rise Over Next 1M For CSTL · CSTL Stock's Historical Performance Compared · How has Castle Biosciences (CSTL) stock price ...10. HealthQuest Capital joined the board of directors in 2014. In 2014, Castle Biosciences landed $11.8 million during a financing round led by new investor HealthQuest Capital. In return for its contribution, Healthquest was given a place on the company’s board of directors.Castle Creek Biosciences: Cell and Gene Therapy Company : Castle Creek Biosciences, Inc. “ We are building a leading cell and gene therapy company for patients and families seeking relief from devastating genetic diseases. ”. Matthew Gantz, President and Chief Executive Officer. Courtesy of debra—The Dystrophic Epidermolysis Bullosa ...

Castle Biosciences, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead ...The all-time high Castle Biosciences stock closing price was 97.33 on February 09, 2021. The Castle Biosciences 52-week high stock price is 29.59, which is 64.4% above the current share price. The Castle Biosciences 52-week low stock price is 9.26, which is 48.6% below the current share price. The average Castle Biosciences stock price for the ...Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2023 Earnings Call Transcript Cathie Wood's Top 15 Small-Cap Stock Picks Small Caps Begin to Rebound: 5 Stocks …

You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently up 8.79% so far this month. During the month of May, Castle Biosciences Inc’s stock price has reached a high of $26.70 and a low of $20.56. Over the last year, Castle Biosciences Inc has hit prices as high as $36.10 and as low as $15.58. Year to date ...

Dec 1, 2023 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma in patients diagnosed with cutaneous melanoma. At Castle Biosciences, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.Castle Biosciences Stock Forecast 11-20-2023. Forecast target price for 11-20-2023: $ 18.23. Negative dynamics for Castle Biosciences shares will prevail with possible volatility of 2.962%. Pessimistic target level: 17.92. Optimistic target level: 18.47.Castle Biosciences Inc (CSTL) Stock Price & News - Google Finance Markets 34,932.41 -0.037% 4,509.11 +0.019% +0.87 14,101.58 -0.086% -12.09 1,795.29 +21.54 VIX 13.72 …

Nov 23, 2023 · Castle Biosciences Inc’s trailing 12-month revenue is $192.0 million with a -39.3% profit margin. Year-over-year quarterly sales growth most recently was 66.2%. Analysts expect adjusted earnings to reach $-2.723 per share for the current fiscal year. Castle Biosciences Inc does not currently pay a dividend.

Castle Biosciences Stock Forecast · Over the next 52 weeks, Castle Biosciences has on average historically fallen by 6.5% based on the past 3 years of stock ...

Castle Biosciences Inc’s trailing 12-month revenue is $192.0 million with a -39.3% profit margin. Year-over-year quarterly sales growth most recently was 66.2%. Analysts expect adjusted earnings to reach $-2.723 per share for the current fiscal year. Castle Biosciences Inc does not currently pay a dividend.Which technical analysis tools can be used to analyze Castle Biosciences, Inc.? Check out various oscillators, moving averages and other technical ...Nikkei 225. 33,424.41. -0.28%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Castle Biosciences Inc (CSTL.OQ) real-time stock quotes, news, price and financial information from ...Nov 24, 2023 · Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. Employment: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: Chimeric antigen receptors (CARs) and CAR-expressing T cells are provided that can specifically target cells that express an elevated level of a target antigen. Likewise, methods for specifically targeting …Insiders trading at Castle Biosciences. Over the last 4 years, insiders at Castle Biosciences have traded over $369,408,068 worth of Castle Biosciences stock and bought 782,652 units worth $12,524,690 . The most active insiders traders include Daniel Bradbury, Derek J Maetzold, and Joseph C. Iii Cook.On average, Castle …Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 25.04% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to ...

Castle Biosciences, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead ...Mar 20, 2023 · Key Insights. Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their trading actions. 51% of the business is held by the top 12 shareholders Castle Biosciences Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall …Castle Biosciences-stock Castle Biosciences Inc Registered Shs Stock , CSTL 19.78 + +% After-market 04:20:00 PM NAS Add to watchlist 19.78 -0.10 -0.50% Official Close …In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Castle Biosciences ( CSTL – Research Report ), with a price target of $43.00. The company’s shares closed ...

Jun 5, 2023 · Shares of Castle Biosciences ( CSTL 2.42%) were down more than 47% on Monday afternoon as three analysts lowered their price targets for the medical diagnostic stock. The healthcare stock is down ... Nov 11, 2021 · The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to ...

Dec 1, 2023 · In the previous week, Castle Biosciences had 4 more articles in the media than Celcuity. MarketBeat recorded 7 mentions for Castle Biosciences and 3 mentions for Celcuity. Castle Biosciences' average media sentiment score of 0.35 beat Celcuity's score of -0.30 indicating that Celcuity is being referred to more favorably in the media. Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 39.75% so far this month. During the month of June, Castle Biosciences Inc’s stock price has reached a high of $24.55 and a low of $9.26. Over the last year, Castle Biosciences Inc has hit prices as high as $36.10 and as low as $9.26. Year to date ...Jun 5, 2023 · Shares of Castle Biosciences ( CSTL 2.42%) were down more than 47% on Monday afternoon as three analysts lowered their price targets for the medical diagnostic stock. The healthcare stock is down ... Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago.Key Insights Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their...Forecst.com predicts future values using technical analysis of a large number of analytical parameters. CSTL stock returns are also predicted based on historical data. According to our research, CSTL stock is a bad long-term investment. CSTL share price has been in a bear cycle for the past year. Castle Biosciences, Inc. stock trend is …Dec 1, 2023 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma in patients diagnosed with cutaneous melanoma. Castle Biosciences Inc (CSTL) Stock Price & News - Google Finance Markets 34,932.41 -0.037% 4,509.11 +0.019% +0.87 14,101.58 -0.086% -12.09 1,795.29 +21.54 VIX 13.72 …

What exchange does Castle Biosciences trade on and what is the company’s stock symbol? Castle Biosciences’ stock is traded on The Nasdaq Global Market under the ticker symbol "CSTL".

Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently up 6.59% so far this month. During the month of November, Castle Biosciences Inc’s stock price has reached a high of $17.08 and a low of $15.28. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to date ...

Simply Wall St. June 8, 2023 at 3:34 AM · 3 min read. The Castle Biosciences, Inc. ( NASDAQ:CSTL) share price has fared very poorly over the last month, falling by a substantial 34%. Instead of ...Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing DecisionDx ®-Melanoma can improve risk stratification over American Joint Committee on Cancer (AJCC) staging alone in patients with stage I cutaneous melanoma …castle sell stock wallpaper. castle biosciences stock buy or sell. Sofinnova Healthquest Partners LP is. The target price for CSTL stock is 8343 based on the average of what a group of analyst thi… Friday, November 11, 2022 Edit. Older Posts Home. Subscribe to: Posts (Atom) Popular Posts. vh1 tv schedule passport. Grandmas in the …In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...The word on The Street in general, suggests a Strong Buy analyst consensus rating for Castle Biosciences with a $34.00 average price target, implying a 67.49% upside from current levels.Castle Biosciences (CSTL) In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Castle Biosciences, with a price target of $38.00 . The company’s shares closed last ...Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently up 22.54% so far this month. During the month of November, Castle Biosciences Inc’s stock price has reached a high of $19.70 and a low of $15.28. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. …These 4 analysts have an average price target of $38.75 versus the current price of Castle Biosciences at $22.02, implying upside. Below is a summary of how these 4 analysts rated Castle ...

Castle Biosciences Stock Up 9.0 %. CSTL stock opened at $14.23 on Tuesday. The company has a market cap of $381.51 million, a PE ratio of -4.25 and a beta of 0.85. The business has a 50-day simple ...Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.47 per share a year ago.These 4 analysts have an average price target of $38.75 versus the current price of Castle Biosciences at $22.02, implying upside. Below is a summary of how these 4 analysts rated Castle ...As soon as the Novitas decision reversal decision was announced, Castle stock began to climb, jumping from ~$13 per share, to nearly $20 per share, a >50% gain that leaves Castle more or less back ...Instagram:https://instagram. trading automation softwarewarren buffett advice to young investorswd40 targetubs credit card The estimated Net Worth of Mara G. Aspinall is at least 2.53 百万$ dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over 1,731,228$ and over the last 8 years she sold CSTL stock worth over 494,800$. In addition, she makes 302,714$ as Independent Director at Castle Biosciences. fanduel biggest winnersretail etfs Dec 1, 2023 · View Castle Biosciences, Inc CSTL investment & stock information. Get the latest Castle Biosciences, Inc CSTL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. The primary residents of European castles during the Middle Ages were the lord and lady of the realm. These might be royalty or simply the liege lords of the district where the castle was built. current ibond interest rate In a report released on July 7, Puneet Souda from SVB Securities maintained a Buy rating on Castle Biosciences (CSTL – Research Report).The company’s shares closed last Friday at $20.30 ...Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new discovery data from an ongoing study exploring the potential for developing a complementary, minimally invasive test to evaluate small, suspicious lesions of uncertain malignant potential in patients’ eyes.